186 related articles for article (PubMed ID: 35503714)
1. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
Liu JJ; Xin B; Du L; Chen L; Long Y; Feng GS
Hepatology; 2023 May; 77(5):1512-1526. PubMed ID: 35503714
[TBL] [Abstract][Full Text] [Related]
2. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
4. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
5. Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Wang Q; Pan W; Wang S; Pan C; Ning H; Huang S; Chiu SH; Chen JL
J Virol; 2021 Feb; 95(6):. PubMed ID: 33361428
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Day JEH; Berdini V; Castro J; Chessari G; Davies TG; Day PJ; St Denis JD; Fujiwara H; Fukaya S; Hamlett CCF; Hearn K; Hiscock SD; Holvey RS; Ito S; Kandola N; Kodama Y; Liebeschuetz JW; Martins V; Matsuo K; Mortenson PN; Muench S; Nakatsuru Y; Ochiiwa H; Palmer N; Peakman T; Price A; Reader M; Rees DC; Rich SJ; Shah A; Shibata Y; Smyth T; Twigg DG; Wallis NG; Williams G; Wilsher NE; Woodhead A; Shimamura T; Johnson CN
J Med Chem; 2024 Mar; 67(6):4655-4675. PubMed ID: 38462716
[TBL] [Abstract][Full Text] [Related]
7. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
[TBL] [Abstract][Full Text] [Related]
8. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY
J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556
[TBL] [Abstract][Full Text] [Related]
9. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Leung CON; Tong M; Chung KPS; Zhou L; Che N; Tang KH; Ding J; Lau EYT; Ng IOL; Ma S; Lee TKW
Hepatology; 2020 Jul; 72(1):155-168. PubMed ID: 31610028
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of SHP2 and its role in cancer.
Asmamaw MD; Shi XJ; Zhang LR; Liu HM
Cell Oncol (Dordr); 2022 Oct; 45(5):729-753. PubMed ID: 36066752
[TBL] [Abstract][Full Text] [Related]
11. Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages.
Du L; Ji Y; Xin B; Zhang J; Lu LC; Glass CK; Feng GS
Cell Mol Gastroenterol Hepatol; 2023; 15(6):1351-1369. PubMed ID: 36828281
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SHP2 as an approach to block RAS-driven cancers.
Chou YT; Bivona TG
Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
[TBL] [Abstract][Full Text] [Related]
13. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
16. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.
Xiang D; Cheng Z; Liu H; Wang X; Han T; Sun W; Li X; Yang W; Chen C; Xia M; Liu N; Yin S; Jin G; Lee T; Dong L; Hu H; Wang H; Ding J
Hepatology; 2017 May; 65(5):1566-1580. PubMed ID: 28059452
[TBL] [Abstract][Full Text] [Related]
17. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481
[TBL] [Abstract][Full Text] [Related]
18. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
[TBL] [Abstract][Full Text] [Related]
19. The function of Shp2 tyrosine phosphatase in the dispersal of acetylcholine receptor clusters.
Qian YK; Chan AW; Madhavan R; Peng HB
BMC Neurosci; 2008 Jul; 9():70. PubMed ID: 18647419
[TBL] [Abstract][Full Text] [Related]
20. SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function.
Chichger H; Braza J; Duong H; Harrington EO
Am J Respir Cell Mol Biol; 2015 Jun; 52(6):695-707. PubMed ID: 25317600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
